Widespread use of contemporary antiretroviral therapy globally has transformed HIV disease into a chronic illness associated with excess risk for disorders of the heart and circulatory system. Current ...

INTRODUCTION Oral manifestations in human immunodeficiency virus (HIV)-infected children are common. The prevalence of these lesions ranges from 20 to 80% depending on patient immune suppression, and ...

The Democratic Republic of the Congo (DRC) has launched a bold new national initiative aimed at eliminating AIDS among children by 2030 - a move hailed by the United Nations as "a beacon of hope" amid ...

Since the onset of the HIV/AIDS epidemic in the early 1980s, close to 15,000 children have been infected with HIV, and approximately 3,000 children have died in the United States from it. Nearly 95 ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

In a major breakthrough in the fight against HIV, the US Food and Drug Administration (FDA) has approved lenacapavir, under the brand name Yeztugo, a long-acting injectable drug developed by Gilead ...

The FDA announced today that they've approved a twice-yearly injection for preventing HIV infection in adults and kids. News ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.… ...

Yeztugo (lenacapavir) is now the first and only HIV prevention option approved by the U.S. FDA that offers protection for six months. Yeztugo received FDA approval under Priority Review.

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...